Serial Assessment of Fertility Experiences

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-10

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease

NCT00305175

Sickle Cell Disease

COMPLETED

Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

NCT04093986

Sickle Cell Disease Sickle Cell Anemia

RECRUITING

Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)

NCT02990598

Sickle Cell Anemia

COMPLETED

SCRIPT: Sickle Cell Risk in Pregnancy Tool

NCT06529042

Sickle Cell Disease Pregnancy, High Risk Pregnancy Complications

ENROLLING_BY_INVITATION

Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated

NCT01609192

Drepanocytic Men Treated by Hydroxyurea for the First Time

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hydroxyurea is a medicine that helps people with sickle cell anemia (SCA), a serious blood disease. It works by increasing a special type of hemoglobin (called fetal hemoglobin) that helps prevent sickle cell problems.

This medicine is especially helpful in places where it's hard to get safe blood transfusions. Studies from around the world have shown that hydroxyurea is safe and can reduce serious health problems caused by SCA (like pain, strokes, and lung issues). It can also help people with SCA live longer, healthier lives.

However, the investigators still don't know everything about how hydroxyurea affects long-term growth, puberty, fertility, or pregnancy; especially in areas with fewer medical resources.

To learn more, researchers are planning a large international study. They will follow people with SCA over time to see how hydroxyurea affects their development, ability to have children, and pregnancy outcomes. Participants will visit the clinic every few months for check-ups, blood tests, and other health assessments. Girls who have started their periods will take pregnancy tests every six months, and boys may be asked to provide a semen sample if they agree. Everyone will also answer questions about their health and fertility regularly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sickle Cell Anemia

Those with sickle cell anemia (SCA).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with documented sickle cell anemia (SCA).
* At least 8 years of age at the time of enrollment.
* Enrolled on the EXTEND or SACRED study.
* Provide informed consent.
* Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.

Exclusion Criteria

* Currently taking part in another treatment study (not EXTEND or SACRED).
* Has received other treatments for sickle cell disease in the past 6 months.

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No